selective imidazoline receptor antagonists
Last reviewed 01/2018
SIRAs are centrally-acting antihypertensive drugs which are thought to target the imidazoline I1 receptor in the cardiovascular control centre in the brainstem.
Monoxidine is the first in this class of drug. Although better tolerated than the older centrally acting antihypertensives such as clonidine, there is no longterm outcome data.
SIRAs should be used when other treatments have been tried and have failed.